The goal of this pilot program sponsored by the Data Science Working Group (DSWG) of the
Legorreta Cancer Center is to seed innovative data science methods and applications that address
key questions in cancer. This pilot award will support a Brown-affiliated team comprising at least one
co-PI who identifies primarily as a data scientist and one co-PI who identifies primarily as a basic,
translational, clinical, or behavioral researcher. The goal of the pilot should be to answer important
cancer-related questions based on existing or newly created data resources. Priority will be given to
proposals that use or develop innovative or creative new methods for analysis, visualization, design,
etc. As well as, to projects that focus on RI or healthcare disparities in RI. These pilot funds are also
intended to enable sufficient preliminary work to support a subsequent R01-equivalent grant
application to the NCI.

Due: December 6, 2024

View the RFA

Overview: This funding announcement aims to support promising and impactful basic and translational research by fostering collaboration between basic scientists and clinicians. The bench-to-bedside and bedside-to-bench approach is designed to effectively translate innovative ideas into practical applications for patients and the wider population. 

Eligible Investigators: Members of the Legorreta Cancer Center, either directly associated with Brown University or affiliated hospital campuses, are eligible to serve as Principal Investigators (PIs) for the grant. Co-investigators and collaborators may include Cancer Center members, individuals from outside academic institutions, or pharmaceutical companies who can meaningfully contribute to the scientific questions or their clinical translation. Non-members are welcome to contact Ms. Shiyoko Cothren to become Cancer Center members before applying for this funding. 

Available Support: We anticipate that at least four projects will receive funding for one year, with a minimum of $25K in direct costs per project. Applicants must clearly justify the need for support and outline the expected impact of their research. Funds will be allocated directly to the research, with no allowance for indirect costs or PI salary support.

Due: Thursday January 2nd, 2025 by 5pm

View the RFA

The Mark Foundation for Cancer Research is now accepting applications to our Drug Discovery Award program. Currently, there are few options for academic scientists to obtain the resources and know-how to advance drug discovery efforts for promising new cancer targets.

To stem this gap, The Mark Foundation has established the Drug Discovery Award program. Through this program, The Mark Foundation aligns with investigators working to discover and progress a new therapeutic agent into preclinical development, providing not only resources to support post-target validation through early lead development but also the expertise of seasoned biopharma R&D scientists who will advise on activities on the critical path to developing a new therapeutic agent.

·     The concept letters are due by November 11, 2024. Invitations for full applications will be issued in January 2025.

·     Applicants may request funding to support a total budget of up to $1,000,000 for a period of 12-36 months

·     The budget limit includes both direct and indirect costs, with indirect costs not to exceed 10% of the direct costs.

·     The proposed work must carry the project forward to a well-defined milestone/value inflection point (e.g., identification of a potent and selective lead or demonstration of in vivo efficacy)

·     Some or all of the proposed work may be carried out at approved contract research organizations (CROs)

·     Eligible therapeutic modalities:

o   Large molecules / biologics

o   Small molecules (including heterobifunctionals)

o   Peptides

o   Conjugates (ADC, radioconjugates)

o   Nucleic acids (ASO, RNA)

·       Eligible project stages:

o   Lead discovery – generate and credential new leads against a validated target

o   Optimization – assess and enhance efficacy, safety, and DMPK of existing leads

·       The following project topics are ineligible for this award:

o   Drug delivery technologies or optimizations

o   Drug repurposing

o   Preclinical development (IND-enabling studies)

o   Cell therapies, gene therapies, viral therapies, and vaccines

The Mark Foundation

The AACR Clinical Oncology Research Training Fellowship program is designed to provide academic clinicians with an effective industry-academic practicum and a unique training opportunity in drug development. The program is for those interested in acquiring the knowledge and skills related to drug development from the perspective of the pharmaceutical industry. The fellow will gain real-world experience in drug development, including clinical research, clinical trial design, and data analysis.

Grants of up to $100,000 will be awarded to support a fellow’s work on-site at the facility of one of AACR’s pharmaceutical industry partners. Time spent at the industry site over the one year may be flexible and is determined on a case-by-case basis between the selected fellow, the fellow’s institution, and the industry partner. The industry partners for this program and their research areas include the following:

Johnson & Johnson (facility location to be agreed to, but possible locations include New Jersey, New York, and the greater Boston and Philadelphia areas): Early-stage and/or late-stage clinical development in oncology therapies for lung cancer, head and neck cancer, and other solid tumors.

To be eligible, applicants must have a medical degree (MD, DO, or MD/PhD) and not currently be a candidate for a further doctoral degree; have enrolled in an accredited hematology/oncology or radiation oncology fellowship program at an academic, medical, or research institution in the United States; and not be an employee or subcontractor of a U.S. government entity or for-profit private industry or a clinical fellow applying from a U.S. government laboratory (e.g., NIH, CDC, FDA, etc.). There are no citizenship requirements.

Deadline: November 30, 2024 at 5:00 p.m. ET

AACR CORE Training Fellowship

Through this Notice of Scientific Interest (NOSI), the National Cancer Institute intends to stimulate research on the role of RNA modifications in the area of cancer biology. Despite the recognition that RNA modifications and editing exert a substantial impact on gene expression and function, there is a lack of mechanistic insights into the dynamic regulation of RNA modifications and their de-regulation as drivers of cancer formation. A better understanding of the extent, diversity, and crosstalk between different types of RNA modification, and the elucidation of the molecular players that read and interpret the modification code are needed to reveal the mechanisms of RNA modifications that underly cancer formation and the cancer phenotype.

Due: Applications open through January 8, 2026

View NOSI

Postdoctoral and clinical fellows are invited to apply for the AACR-Johnson & Johnson Interventional Oncology (START) Grants. These three-year, $225,000 fellowships offer training in both academia and industry, with one year at a Johnson & Johnson facility.

Research proposals may be basic, translational, or clinical in nature, but must have direct applicability to lung cancer. Proposals focused on mechanisms linking immunogenic cell death pathways to amplification of innate and adaptive immunity, immunobiology of non-small cell lung cancers, and mechanisms of acquired resistance to immunotherapies are highly encouraged.  

Due: January 14th by 1PM

View RFA

The Conquer Cancer – Breast Cancer Research Foundation Advanced Clinical Research Award (ACRA) for Diversity and Inclusion in Breast Cancer Research is designed with the primary goal of increasing diversity in the oncology workforce and breast cancer research. Awards will be given to mid-career investigators who identify as members of populations underrepresented in medicine (UIM)*, and who wish to conduct original breast cancer research not currently funded.

Funding Available

The total award amount is $450,000 over three years, payable in annual increments of $150,000. Conquer Cancer has funding for two BCRF ACRAs for Diversity and Inclusion in Breast Cancer Research which will be awarded to the most meritorious applications evaluated for this competition.

Due: January 31, 2025

View RFA

Unlimited funding, Rolling application 

Bold ideas to help children with brain tumors can come at any time. The Pediatric Brain Tumor Foundation accepts and evaluates requests for research funding on an ongoing basis throughout the year so that researchers are able to develop these ideas into the next scientific breakthrough. There are no deadlines, and we encourage investigators to apply at their earliest convenience.

Pediatric Brain Tumor Foundation Research Grant

The American Cancer Society (ACS) aims to improve the lives of people with cancer and their families through advocacy, research, and patient support and to ensure everyone has an opportunity to prevent, detect, treat, and survive cancer.

The ACS invites applications for the Clinician Scientist Development Grant (CSDG) program, which supports full-time faculty members in becoming independent investigators as clinician-scientists. This grant is designed for people trained primarily as clinicians who want to maintain clinical practice and conduct cancer research.

Grants of $135,000 a year for direct costs plus 8 percent allowable indirect costs will be awarded for three to five years.

To be eligible, applicants must work at a U.S. academic institution or eligible nonprofit, have a doctoral degree, an active clinical license, and participate in clinical care, not be a current or former primary investigator (PI) of an individual mentored training grant, and have not had an R-level or equivalent grant as PI.

For complete program guidelines and application instructions, see the American Cancer Society website.

American Cancer Society RFP